Aspirin for venous thromboprophylaxis after fracture: ready for prime time?
- PMID: 36869746
- DOI: 10.1093/eurheartj/ehad098
Aspirin for venous thromboprophylaxis after fracture: ready for prime time?
Conflict of interest statement
Conflict of interest R.V. received speaker’s fees from Abbott Vascular, Amgen and Terumo, outside the submitted work. C.P. received consultant and speaker fees from Acticor Biotech, Amgen, Bayer, GlaxoSmithKline, Tremeau, Zambon, and grant support (to the Institution) for investigator-initiated research from AIFA (Italian Drug Agency), Bayer, Cancer Research UK and European Commission; he chairs the Scientific Advisory Board of the International Aspirin Foundation.
Comment on
-
Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture.N Engl J Med. 2023 Jan 19;388(3):203-213. doi: 10.1056/NEJMoa2205973. N Engl J Med. 2023. PMID: 36652352 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources